IVIG in autoimmunity and cancer - Efficacy versus safety

Expert Opinion on Drug Safety

Volumn 1, Issue 2, 2002, Pages 153-158

  Sherer, Yaniv ^a   Levy, Yair ^a   Shoenfeld, Yehuda ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

adverse effect; autoimmune disease; cancer; intravenous immunoglobulin

Indexed keywords

IMMUNOGLOBULIN;

AUTOIMMUNE DISEASE; CELL CULTURE; CLINICAL TRIAL; DRUG EFFECT; EXPERT WITNESS; HUMAN; IMMUNOLOGY; NEOPLASM; REVIEW; SAFETY;

AUTOIMMUNE DISEASES; CLINICAL TRIALS; EXPERT TESTIMONY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; NEOPLASMS; SAFETY; TUMOR CELLS, CULTURED;

EID: 0041735267     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.1.2.153     Document Type: Review

References (36)

1. CANCER AND AUTOIMMUNITY: Shoenfeld Y, Gershwin ME (eds), Elsevier, Amsterdam (2000):1-446.
2. CORVETTA A, DELLA BITTA R, GABRIELLI A, SPAETH PJ, DANIELLI G: Use of high-dose intravenous immunoglobulin in systemic lupus erythematosus: report of three cases. Clin. Exp. Rheumatol. (1989) 7:295-299. (Pubitemid 19200339)
3. LIN CY, HSU HC, CHIANG H: Improvement of histological and immunological change in steroid and immunosuppressive drug-resistant lupus nephritis by high-dose intravenous gamma globulin. Nephron (1989) 53:303-310. (Pubitemid 19267243)
4. SCHROEDER JO, ZEUNER RA, EULER HH, LOFFLER H: High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study. J. Rheumatol. (1996) 23:71-75. (Pubitemid 26037213)
5. FRANCIONI C, GALEAZZI M, FIORAVANTI A, GELLI R, MEGALE F, MARCOLONGO R: Long term i.v. Ig treatment in systemic lupus erythematosus. Clin. Exp. Rheumatol. (1994) 12:163-168. (Pubitemid 24159181)
6. MAIER WP, GORDON DS, HOWARD RF et al.: Intravenous immunoglobulin therapy in systemic lupus erythematosusassociated thrombocytopenia. Arthritis Rheum. (1990) 33:1233-1239. (Pubitemid 20273312)
7. DE PITA O, BELLUCCI AM, RUFFELLI M, GIRARDELLI CR, PUDDU P: Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosus. Lupus (1997) 6:415-417.
8. LEVY Y, SHERER Y, AHMED A et al.: A study of 20 SLE patients with intravenous immunoglobulin-clinical and serologic response. Lupus (1999) 8:705-712.
9. SHERER Y, LEVY Y, LANGEVITZ P, LORBER M, FABRIZZI F, SHOENFELD Y: Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin. Clin. Rheumatol. (1999) 18:170-173. (Pubitemid 29223043)
10. SHERER Y, LEVY Y, SHOENFELD Y: Marked improvement of severe cardiac dysfunction after one course of intravenous immunoglobulin in a patient with systemic lupus erythematosus. Clin. Rheumatol. (1999) 18:238-240. (Pubitemid 29284723)
11. JAYNE DR, LOCKWOOD CM: Pooled intravenous immunoglobulin in the management of systemic vasculitis. Adv. Exp. Med. Biol. (1993) 336:469-472. (Pubitemid 24004971)
12. RICHTER C, SCHNABEL A, CSERNOK E, DE-GROOT K, REINHOLD-KELLER E, GROSS WL: Treatment of antineutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin. Exp. Immunol. (1995) 101:2-7.
13. ROSTOKER G, DESVAUX-BELGHITI D, PILATTE Y et al.: High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Schonlein purpura. Ann. Intern. Med. (1994) 120:476-484.
14. LEVY Y, SHERER Y, GEORGE J et al.: Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin. Int. Arch. Allergy Immunol. (1999) 119:231-238. (Pubitemid 29326997)
15. MCLEAN HJ, FREEDMAN MS: Immunologic therapy for relapsingremitting multiple sclerosis. Curr. Neurol. Neurosci. Rep. (2001) 1:277-285.
16. RONAGER J, RAVNBORG M, HERMANSEN I, VORSTRUP S: Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif. Organs. (2001) 25:967-973. (Pubitemid 34107305)
17. LEVY Y, SHERER Y, LANGEVITZ P et al.: Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin-a preliminary report. Clin. Rheumatol. (2000) 19:207-211. (Pubitemid 30341255)
18. LEVY Y, SHERER Y, AHMED A et al.: Autoantibody level modification in adult patients with idiopathic thrombocytopenic purpura following intravenous immunoglobulin treatment. Nat. Immun. (1998) 16:207-214.
19. YAP PL: Prevention of infections in patients with B cell defects: focus on intravenous immunoglobulin. Clin. Infect. Dis. (1993) 17(Suppl. 2):372-375.
20. GAMM H, HUBER C, CHAPEL H et al.: Intravenous immune globulin in chronic lymphocytic leukaemia. Clin. Exp. Immunol. (1994) 97(Suppl. 1):17-20. (Pubitemid 24235261)
21. CHAPEL HM, LEE M, HARGREAVES R et al.: Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK group for immunoglobulin replacement therapy in multiple myeloma. Lancet (1994) 343:1059-1063. (Pubitemid 24128204)
22. BODE U, ERPS M, LIAPPIS N: Immunoglobulin administration in infection prevention in oncologic patients. Klin. Padiatr. (1986) 198:476-478. (Pubitemid 17201236)
23. HADJILASKARI P, ROEHRIG G, HARTMANN R et al.: Effect of 7S immunoglobulin substitution on the incidence and course of infection in cytostatic drug treated patients. Klin. Padiatr. (1990) 202:275-277.
24. ABEDI MR, LINDE A, CHRISTENSSON B et al.: Preventive effect of IgG from EBVseropositive donors on the development of human lympho-proliferative disease in SCID mice. Int. J. Cancer (1997) 71:624-629. (Pubitemid 27239374)
25. KRAUSE I, WU R, SHERER Y et al.: In vitro anti-viral and anti-bacterial activity of commercial intravenous immunoglobulin preparations-a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Tranfus. Med. (2002). In press.
26. SHOENFELD Y, FISHMAN P: Gammaglobulin inhibits tumor spread in mice. Int. Immunol. (1999) 11:1247-1252.
27. MERIMSKY O, MELLER I, INBAR M et al.: A possible role for IVIg in the treatment of soft tissue sarcoma: a clinical case and an experimental model. Int. J. Oncol. (2002) 20:839-843.
28. SHOENFELD Y, LEVY Y, FISHMAN P: Shrinkage of melanoma metastases following high dose intravenous immunoglobulin treatment. Isr. Med. Assoc. J. (2001) 3:698-699. (Pubitemid 34044168)
29. BAR-DAYAN Y, BARSHACK I, BLANK M et al.: Antibodies to the cytoplasm, cell membrane and nuclear membrane of malignant neoplasms in pooled normal human polyspecific immunoglobulin G. Int. J. Oncol. (1999) 15:1091-1096.
30. NYDEGGER UE, STURZENEGGER M: Adverse effects of intravenous immunoglobulin therapy. Drug. Saf. (1999) 21:171-185. (Pubitemid 29427880)
31. SULLIVAN KM, STOREK J, KOPECKY KJ et al.: A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft versus host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. Biol. Blood. Marrow. Transplant. (1996) 2:44-53. (Pubitemid 126488195)
32. SHERER Y, LEVY Y, LANGEVITZ P et al.: Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacology (2001) 62:133-137. (Pubitemid 32260852)
33. BRANNAGAN TH III, NAGLE KJ, LANGE DJ, ROWLAND LP: Complications of intravenous immune globulin treatment in neurologic disease. Neurology (1996) 47:674-677. (Pubitemid 26307296)
34. SCHIAVOTTO C, RUGGERI M, RODEGHIERO F: Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica (1993) 78:35-40.
35. BAGDASARIAN A, TONETTA S, HAREL W et al.: IVIG adverse reactions: potential role of cytokines and vasoactive substances. Vox. Sang. (1998) 74:74-82. (Pubitemid 28052448)
36. CANTU TG, HOEHN-SARIC EW, BURGESS KM et al.: Acute renal failure associated with immunoglobulin therapy. Am. J. Kidney. Dis. (1995) 25:228-234.